Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin - ScienceDirect
Large NOAC trial stopped early as primary endpoint was reached ahead of time - PACE-CME
MEDVASC - VOYAGER : le rivaroxaban 2,5 mg X 2, c'est oui
The COMPASS Trial | Circulation
COMPASS : Rivaroxaban + aspirine chez le vasculaire
Stroke Outcomes in the COMPASS Trial | Circulation
Épisode 10 : Étude COMPASS - BaladoCritique : Club de lecture médical - Université de Sherbrooke
Study design of COMPASS. To assess the safety and efficacy of... | Download Scientific Diagram
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios | Current Cardiology Reports
C. Michael Gibson MD on X: "Here is the design of the COMPASS trial of > 27,000 patients that was shut down due to overwhelming superiority of rivaroxaban https://t.co/abziReBQNk" / X
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial - ScienceDirect
Eikelboom Net Clinical Benefit Video | XARELTO® (rivaroxaban)
COMPASS Trial Insights into Aspirin and Rivaroxaban Combined Therapy, October 13 2017 - YouTube
Peripheral Artery Disease, the Factor Xa Inhibitor Rivaroxaban, and the Role of the Podiatrist
Rivaroxaban con o sin Aspirina en enfermedad cardiovascular estable – Estudio COMPASS
Efficacy Profile - Chronic CAD/PAD | XARELTO® (rivaroxaban) HCP
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial - The Lancet
COMPASS study of Janssen's rivaroxaban to end early for efficacy - 526 Fulham Rd, Fulham, London SW6, UK
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial | Journal of the American College of Cardiology
Studio COMPASS: efficacia dell'associazione rivaroxaban ed aspirina nei pazienti con vasculopatia aterosclerotica stabile - ATBV
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease | Heart
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial | Journal of the American College of Cardiology
COMPASS Trial Shows Rivaroxaban and Aspirin Lowers Major Adverse Limb Events in Peripheral Artery Disease | DAIC
COMPASS: Clinical Trial - Post Revascularization & Chronic PAD | XARELTO® ( rivaroxaban) HCP
Combining rivaroxaban with aspirin in stable atherosclerotic vascular disease: clinical evidence from the COMPASS study - The British Journal of Cardiology
The COMPASS Trial | Circulation
